260 related articles for article (PubMed ID: 33109034)
1. Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning.
Zhao Y; Liu Y; Bai H
Comb Chem High Throughput Screen; 2021; 24(9):1340-1350. PubMed ID: 33109034
[TBL] [Abstract][Full Text] [Related]
2. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
Lee H; Kang S; Kim W
PLoS One; 2016; 11(3):e0150460. PubMed ID: 26954019
[TBL] [Abstract][Full Text] [Related]
3. Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS).
Vempati UD; Chung C; Mader C; Koleti A; Datar N; Vidović D; Wrobel D; Erickson S; Muhlich JL; Berriz G; Benes CH; Subramanian A; Pillai A; Shamu CE; Schürer SC
J Biomol Screen; 2014 Jun; 19(5):803-16. PubMed ID: 24518066
[TBL] [Abstract][Full Text] [Related]
4. Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.
Lu Y; Boswell W; Boswell M; Klotz B; Kneitz S; Regneri J; Savage M; Mendoza C; Postlethwait J; Warren WC; Schartl M; Walter RB
Sci Rep; 2019 Jan; 9(1):530. PubMed ID: 30679619
[TBL] [Abstract][Full Text] [Related]
5. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
6. Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma.
Han C; Yu X; Zhang C; Cai Y; Cao Y; Wang S; Shen J
Comb Chem High Throughput Screen; 2019; 22(7):483-495. PubMed ID: 31526347
[TBL] [Abstract][Full Text] [Related]
7. The Use of Large-Scale Chemically-Induced Transcriptome Data Acquired from LINCS to Study Small Molecules.
Iwata M; Yamanishi Y
Methods Mol Biol; 2019; 1888():189-203. PubMed ID: 30519948
[TBL] [Abstract][Full Text] [Related]
8. Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes.
Xu C; Ai D; Shi D; Suo S; Chen X; Yan Y; Cao Y; Zhang R; Sun N; Chen W; McDermott J; Zhang S; Zeng Y; Han JJ
Cell Rep; 2018 Oct; 25(2):523-535.e5. PubMed ID: 30304690
[TBL] [Abstract][Full Text] [Related]
9. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.
Cheng F; Zhao J; Fooksa M; Zhao Z
J Am Med Inform Assoc; 2016 Jul; 23(4):681-91. PubMed ID: 27026610
[TBL] [Abstract][Full Text] [Related]
10. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
11. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
Zador Z; King AT; Geifman N
PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic Data Mining and Repurposing for Computational Drug Discovery.
Wang Y; Yella J; Jegga AG
Methods Mol Biol; 2019; 1903():73-95. PubMed ID: 30547437
[TBL] [Abstract][Full Text] [Related]
13. A Review of Drug Repositioning Based Chemical-induced Cell Line Expression Data.
Wang F; Lei X; Wu FX
Curr Med Chem; 2020; 27(32):5340-5350. PubMed ID: 30381060
[TBL] [Abstract][Full Text] [Related]
14. Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy.
Temesi G; Bolgár B; Arany A; Szalai C; Antal P; Mátyus P
Future Med Chem; 2014 Apr; 6(5):563-75. PubMed ID: 24649958
[TBL] [Abstract][Full Text] [Related]
15. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer.
Norkin M; Ordóñez-Morán P; Huelsken J
Cell Rep; 2021 Apr; 35(3):109026. PubMed ID: 33882314
[TBL] [Abstract][Full Text] [Related]
16. PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.
Emon MA; Domingo-Fernández D; Hoyt CT; Hofmann-Apitius M
BMC Bioinformatics; 2020 Jun; 21(1):231. PubMed ID: 32503412
[TBL] [Abstract][Full Text] [Related]
17. Compound signature detection on LINCS L1000 big data.
Liu C; Su J; Yang F; Wei K; Ma J; Zhou X
Mol Biosyst; 2015 Mar; 11(3):714-22. PubMed ID: 25609570
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
Lee OW; Austin S; Gamma M; Cheff DM; Lee TD; Wilson KM; Johnson J; Travers J; Braisted JC; Guha R; Klumpp-Thomas C; Shen M; Hall MD
SLAS Discov; 2020 Jan; 25(1):9-20. PubMed ID: 31498718
[TBL] [Abstract][Full Text] [Related]
19. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles.
Kim IW; Jang H; Kim JH; Kim MG; Kim S; Oh JM
Sci Rep; 2019 Feb; 9(1):2660. PubMed ID: 30804389
[TBL] [Abstract][Full Text] [Related]
20. Drug repositioning based on gene expression data for human HER2-positive breast cancer.
Khanjani F; Jafari L; Azadiyan S; Roozbehi S; Moradian C; Zahiri J; Hasannia S; Sajedi RH
Arch Biochem Biophys; 2021 Nov; 712():109043. PubMed ID: 34597657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
